​In this week's edition...
 
— PIPC Responds to CMS' GLOBE and GUARD Models, Also Known as 'Most Favored Nation.' Click here to read PIPC's full statement.
— RealClear Discusses 'Most Favored Nation,' Criticizing the Policy's Impact on Patient Access. Click here to view the article.
— MFN May Also Cut Off Rural America. Click here to view the article.
— The Well News (Opinion): Most Favored Nation Drug Pricing Fails Patients and their Caregivers. View the opinion here.
— PIPC Data Mine Blog: Why Patients Shouldn’t Bear Individual Harms for Better Population Averages. View the new PIPC Data Mine Blog here.
— PIPC Chairman Coelho Testifies to Oregon Department of Consumer and Business Services. View Chairman Coelho’s testimony here. View the testimony from Disability Rights Oregon here. Learn more about the hearing here.
— White House Issues RFI on Scientific Research & AI. See details below.
— Prasad and Makary Discuss Novel FDA Plausible Mechanism Pathway. Click here to read the NEJM publication.
— Reps. Cammack and Hern Introduce QALY Ban Bill. See details below.
— Opportunity: Sign an Open Letter Rejecting Use of QALYs and Similar Measures. See details below.
— Update on the Texas v. Kennedy Lawsuit. See details below.
— Emerging Threats in States for Use of Discriminatory Metrics. See details below.
— What Happens in Countries Using QALYs and Cost-Based Thresholds? See details below.
— ICER's QALY-Based Study Topics. See details below.
— Upcoming Events and Webinars. See details below.

​PIPC appreciates the administration’s goals to lower health costs for patients. PIPC remains concerned that the latest proposals to advance a Most Favored Nation pricing model for drugs will, in effect, import the worst of foreign health systems – their reliance on discriminatory value assessments. Stories from outside the U.S., like that of the Williams’ family, illustrate why quality-adjusted life years (QALYs) have no place in U.S. policy. Patients do not have the luxury of time.

In this week's edition...
 
— The Well News (Opinion): Most Favored Nation Drug Pricing Fails Patients and their Caregivers. View the opinion here.
— PIPC Data Mine Blog: Why Patients Shouldn’t Bear Individual Harms for Better Population Averages. View the new PIPC Data Mine Blog here.
— PIPC Responds to Medicare Negotiation Program’s Prices. View PIPC’s complete statement here. 
— PIPC Chairman Coelho Testifies to Oregon Department of Consumer and Business Services. View Chairman Coelho’s testimony here. View the testimony from Disability Rights Oregon here. Learn more about the hearing here.
— White House Issues RFI on Scientific Research & AI. See details below.
— PIPC Statement on GENEROUS Model, also known as “Most Favored Nation." View the statement here.
— Prasad and Makary Discuss Novel FDA Plausible Mechanism Pathway. Click here to read the NEJM publication.
— Reps. Cammack and Hern Introduce QALY Ban Bill. See details below.
— Opportunity: Sign an Open Letter Rejecting Use of QALYs and Similar Measures. See details below.
— Update on the Texas v. Kennedy Lawsuit. See details below.
— Emerging Threats in States for Use of Discriminatory Metrics. See details below.
— What Happens in Countries Using QALYs and Cost-Based Thresholds? See details below.
— ICER's QALY-Based Study Topics. See details below.
— Upcoming Events and Webinars. See details below.

​The recent draft Health Technology Assessment (HTA) methods report released by the Health Economics Methods Advisory group makes it crystal clear – policy grounded in conventional HTA methods (like the QALY) are willing to harm the individual for the sake of the formula-derived average. 

PIPC shared the following statement highlighting its appreciation for the Trump Administration’s goal of lowering health care costs for patients awhile sharing continued concerns over the subjectivity and lack of transparency in the process for selecting a Maximum Fair Price (MFP), limited consideration of patient perspectives, and potential for continued reliance on value assessments conducted by the Institute for Clinical and Economic Review. 

In this week's edition...
 
— PIPC Responds to Medicare Negotiation Program’s Prices. View PIPC’s complete statement here. 
— White House Issues RFI on Scientific Research & AI. See details below.
— Oregon Invites ICER to Hearing on Pricing Despite Statewide QALY Ban. More information is available here.
— Draft HEMA Report: USC Schaeffer Makes Case Against Accepting Individual Harms to Improve Population Averages. View USC Schaeffer’s response to the draft report here.
— PIPC Statement on GENEROUS Model, also known as “Most Favored Nation." View the statement here.
— Prasad and Makary Discuss Novel FDA Plausible Mechanism Pathway. Click here to read the NEJM publication.
— New PQA Patient Advisory Council Seeks Nominations. Individuals can submit their nominations via this form. Additional details are provided in a recent PQA blog.
— PCORI Discusses the Importance of Patient-Centered Comparative CER Research. Click here to read more.
— Reps. Cammack and Hern Introduce QALY Ban Bill. See details below.
— Opportunity: Sign an Open Letter Rejecting Use of QALYs and Similar Measures. See details below.
— Update on the Texas v. Kennedy Lawsuit. See details below.
— Emerging Threats in States for Use of Discriminatory Metrics. See details below.
— What Happens in Countries Using QALYs and Cost-Based Thresholds? See details below.
— ICER's QALY-Based Study Topics. See details below.
— Upcoming Events and Webinars. See details below.

In this week's edition...
 
— PIPC Statement on GENEROUS Model, also known as “Most Favored Nation." View the statement here.
— Prasad and Makary Discuss Novel FDA Plausible Mechanism Pathway. Click here to read the NEJM publication.
— New PQA Patient Advisory Council Seeks Nominations. Individuals can submit their nominations via this form. Additional details are provided in a recent PQA blog.
— Draft HEMA Report: USC Schaeffer Makes Case Against Accepting Individual Harms to Improve Population Averages. View USC Schaeffer’s response to the draft report here.
— PCORI Discusses the Importance of Patient-Centered Comparative CER Research. Click here to read more.
— Health Affairs: PIPC Chairman Highlights PDAB Shortcomings. Click here to view the article. 
-- The Baltimore Sun: Maryland's Drug Affordability Board Has Been a Failure. View the opinion here. 
— PIPC Chairman Explains that the MFN is Exacting Too High a Price for Patients and People with Disabilities. Click here to read the statement.
— SFS Releases Survey Results Detailing Americans' Rejection of Foreign Drug Pricing Schemes. See details below.
— Reps. Cammack and Hern Introduce QALY Ban Bill. See details below.
— Opportunity: Sign an Open Letter Rejecting Use of QALYs and Similar Measures. See details below.
— Update on the Texas v. Kennedy Lawsuit. See details below.
— Emerging Threats in States for Use of Discriminatory Metrics. See details below.
— What Happens in Countries Using QALYs and Cost-Based Thresholds? See details below.
— ICER's QALY-Based Study Topics. See details below.
— Upcoming Events and Webinars. See details below.

The Partnership to Improve Patient Care (PIPC) has issued the following statement in response to the Trump administration's "GENEROUS" model. 

In this week's edition...
 
— Health Affairs: PIPC Chairman Highlights PDAB Shortcomings. Click here to view the article. 
— ICER Again Fails to Address Patient and Disability Concerns Related to its Biased Methodology. View PIPC’s Data Mine blog related to the methodology and protocol here.
-- The Baltimore Sun: Maryland's Drug Affordability Board Has Been a Failure. View the opinion here. 
— PIPC Response to Trump Administration’s Continued Push for MFN Pricing. Click here to view the statement.
— PharmaPhorum Discusses the Affordability of Medicines and Innovation. Click here to read the article.
— PIPC Chairman Explains that the MFN is Exacting Too High a Price for Patients and People with Disabilities. Click here to read the statement.
— SFS Releases Survey Results Detailing Americans' Rejection of Foreign Drug Pricing Schemes. See details below.
— Reps. Cammack and Hern Introduce QALY Ban Bill. See details below.
— Opportunity: Sign an Open Letter Rejecting Use of QALYs and Similar Measures. See details below.
— Update on the Texas v. Kennedy Lawsuit. See details below.
— Emerging Threats in States for Use of Discriminatory Metrics. See details below.
— What Happens in Countries Using QALYs and Cost-Based Thresholds? See details below.
— ICER's QALY-Based Study Topics. See details below.
— Upcoming Events and Webinars. See details below.

In this week's edition...
 
— Health Affairs: PIPC Chairman Highlights PDAB Shortcomings. Click here to view the article. 
— TODAY: NMQF Patient-Centered Physical Laws Framework (PLF) and MFN. Register to join here.
— ICER Again Fails to Address Patient and Disability Concerns Related to its Biased Methodology. View PIPC’s Data Mine blog related to the methodology and protocol here.
— PIPC Response to Trump Administration’s Continued Push for MFN Pricing. Click here to view the statement.
— Pharmaphorum Discusses the Affordability of Medicines and Innovation. Click here to read the article.
— PIPC Chairman Explains that the MFN is Exacting Too High a Price for Patients and People with Disabilities. Click here to read the statement.
— SFS Releases Survey Results Detailing Americans' Rejection of Foreign Drug Pricing Schemes. See details below.
— Data Mine Blog Analyzes a New Study from OHE on International Reference to QALYs. See details below.
— Reps. Cammack and Hern Introduce QALY Ban Bill. See details below.
— Opportunity: Sign an Open Letter Rejecting Use of QALYs and Similar Measures. See details below.
— Update on the Texas v. Kennedy Lawsuit. See details below.
— Emerging Threats in States for Use of Discriminatory Metrics. See details below.
— What Happens in Countries Using QALYs and Cost-Based Thresholds? See details below.
— ICER's QALY-Based Study Topics. See details below.
— Upcoming Events and Webinars. See details below.

In this week's edition...
 
— Health Affairs: Sisters Working It Out Highlights PDAB Shortcomings. Click here to view the article. 
— POLITICO: Britain prepares NHS drug spending hike to stave off Trump tariffs. Click here to view the article.
— PIPC Response to Trump Administration’s Continued Push for MFN Pricing. Click here to view the statement.
— Pharmaphorum Discusses the Affordability of Medicines and Innovation. Click here to read the article.
— Engaging Medicaid Members and Community-Based Organizations Through Beneficiary Advisory Councils. Click here to learn more.
— PIPC Chairman Explains that the MFN is Exacting Too High a Price for Patients and People with Disabilities. Click here to read the statement.
— Thyroid Foundation Hosts Webinar on Patient Access. Click here to RSVP.
— SFS Releases Survey Results Detailing Americans' Rejection of Foreign Drug Pricing Schemes. See details below.
— Data Mine Blog Analyzes a New Study from OHE on International Reference to QALYs. See details below.
— Reps. Cammack and Hern Introduce QALY Ban Bill. See details below.
— Opportunity: Sign an Open Letter Rejecting Use of QALYs and Similar Measures. See details below.
— Update on the Texas v. Kennedy Lawsuit. See details below.
— Learn More About Alternative Measures for Value Assessment. Click here to learn more.
— Emerging Threats in States for Use of Discriminatory Metrics. See details below.
— What Happens in Countries Using QALYs and Cost-Based Thresholds? See details below.
— ICER's QALY-Based Study Topics. See details below.
— Upcoming Events and Webinars. See details below.

In this week's edition...
 
— PIPC Response to Trump Administration’s Continued Push for MFN Pricing. Click here to view the statement.
— Pharmaphorum Discusses the Affordability of Medicines and Innovation. Click here to read the article.
— Engaging Medicaid Members and Community-Based Organizations Through Beneficiary Advisory Councils. Click here to learn more.
— PIPC Chairman Explains that the MFN is Exacting Too High a Price for Patients and People with Disabilities. Click here to read the statement.
— Thyroid Foundation Hosts Webinar on Patient Access. Click here to RSVP.
— SFS Releases Survey Results Detailing Americans' Rejection of Foreign Drug Pricing Schemes. See details below.
— Data Mine Blog Analyzes a New Study from OHE on International Reference to QALYs. See details below.
— Reps. Cammack and Hern Introduce QALY Ban Bill. See details below.
— Opportunity: Sign an Open Letter Rejecting Use of QALYs and Similar Measures. See details below.
— Update on the Texas v. Kennedy Lawsuit. See details below.
— Learn More About Alternative Measures for Value Assessment. Click here to learn more.
— Emerging Threats in States for Use of Discriminatory Metrics. See details below.
— What Happens in Countries Using QALYs and Cost-Based Thresholds? See details below.
— ICER's QALY-Based Study Topics. See details below.
— Upcoming Events and Webinars. See details below.

The Partnership to Improve Patient Care (PIPC) has issued the following statement in response to the Trump administration's consideration of "Most Favored Nations" policy in the U.S.

In this week's edition...
 
— PIPC Response to Trump Administration’s Continued Push for MFN Pricing. Click here to view the statement.
— Engaging Medicaid Members and Community-Based Organizations Through Beneficiary Advisory Councils. Click here to learn more.
— PIPC Chairman Explains that the MFN is Exacting Too High a Price for Patients and People with Disabilities. Click here to read the statement.
— SFS Releases Survey Results Detailing Americans' Rejection of Foreign Drug Pricing Schemes. See details below.
— Bonnell Foundation in Detroit News: Critique of MFN as an Avenue for Drug Pricing Reform. Click here to read the article.
— Patient Organizations Send Letter to Washington PDAB. See details below.
— ICHOM Working Group: Kidney Stones Set Feedback Opportunity. See details below.
— PIPC Comment to CMS on ICR Emphasizes QALY Transparency. See details below.
— PIPC Urges Minnesota PDAB to Reject Discriminatory Value Assessments. Click here to read the letter.
— CMS Referenced QALYs in Explanations for Medicare Drug Price Negotiation Program. See details below.
— EACH/PIC Releases Results from Patient-Led Survey on Drug Affordability. See details below.
— Data Mine Blog Analyzes a New Study from OHE on International Reference to QALYs. See details below.
— Reps. Cammack and Hern Introduce QALY Ban Bill. See details below.
— Opportunity: Sign an Open Letter Rejecting Use of QALYs and Similar Measures. See details below.
— National Minority Quality Forum Issue Brief Details MFN Consequences. Click here to read the issue brief.
— Update on the Texas v. Kennedy Lawsuit. See details below.
— Learn More About Alternative Measures for Value Assessment. Click here to learn more.
— Emerging Threats in States for Use of Discriminatory Metrics. See details below.
— What Happens in Countries Using QALYs and Cost-Based Thresholds? See details below.
— ICER's QALY-Based Study Topics. See details below.
— Upcoming Events and Webinars. See details below.

In his latest "Chairman's Corner" blog, PIPC Chairman Tony Coelho explains why the "Most Favored Nation" approach to drug pricing will only serve to increase costs for patients and people with disabilities.